Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade.

"Competing interests: JSD receives research funding from Bristol-Myers Squibb. DW is an employee of Merck. EJL serves as a consultant/advisory board member for Array BioPharma, Bristol-Myers Squibb, EMD Serono, Genentech, Macrogenics, Merck, Millennium, Novartis, Sanofi/Regeneron, and receives institutional research funding from Bristol-Myers Squibb, Merck and Regeneron. JMT serves as a consultant/advisory board member for Bristol-Myers Squibb, Merck, AstraZeneca, Compugen, and Akoya Biosciences. No additional potential conflicts of interest were disclosed."

"Funding: This work was supported by The Mark Foundation for Advanced Genomics and Imaging at Johns Hopkins (JMT, EJL); National Cancer Institute R01 CA142779 (JMT), National Institutes of Health Training grant T32CA193145 (AS, JSD), The Bloomberg~Kimmel Institute for Cancer Immunotherapy (JSD, KMS, LLE, EJL, JMT), The Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research (KMS, EJL), and Bristol-Myers Squibb (JSD, EJL, JMT)."